January 6, 2024

FDA Com­mis­sion­er Rob Califf and bi­o­log­ics di­rec­tor Pe­ter Marks took to JA­MA on Fri­day to counter the cur­rent “large vol­ume” of vac­cine mis­in­for­ma­tion by urg­ing

Il­lu­mi­na di­rec­tors have al­leged that an ac­tivist who joined the board last year im­prop­er­ly sup­plied con­fi­den­tial in­for­ma­tion to in­vestor Carl Ic­ahn for use in his

GSK’s Vi­iV Health­care is get­ting in­to a new kind of race on Fri­day — “Ru­Paul’s Drag Race” re­al­i­ty show on MTV — as the spon­sor

The block­buster type 2 di­a­betes and obe­si­ty drug semaglu­tide was as­so­ci­at­ed with a low­er risk of sui­ci­dal ideation com­pared to oth­er obe­si­ty and type 2

Fu­sion Phar­ma­ceu­ti­cals said it has man­u­fac­tured the first clin­i­cal dose of its ra­dio­phar­ma­ceu­ti­cal as­set in-house and has agreed with the FDA on the de­sign of

In 2015, psy­chi­a­trist Saman­tha Meltzer-Brody saw an un­be­liev­able trans­for­ma­tion in a new moth­er who had been ad­mit­ted to her psy­chi­a­try clin­ic. With­drawn and hav­ing sui­ci­dal

No­var­tis has the go-ahead from the FDA to man­u­fac­ture its ra­dio­phar­ma­ceu­ti­cal Plu­vic­to at a new fa­cil­i­ty in In­di­anapo­lis, mark­ing a step to­ward ad­dress­ing bur­geon­ing de­mand.

Not want­i­ng to be left out in the cold, Mer­ck now plans to pur­sue GLP-1 com­bi­na­tion ther­a­pies amid grow­ing ex­cite­ment about the lu­cra­tive po­ten­tial of a drug class that

IQVIA is call­ing off its ac­qui­si­tion of Pro­pel Me­dia and health tech mar­keter Deep­In­tent. The com­pa­nies agreed to aban­don the deal af­ter an FTC probe

Plus, news about PolyPid, Claram­e­tyx Bio­sciences, De­bio­pharm, Re­pare Ther­a­peu­tics, Im­mu­nic, Voy­ager Ther­a­peu­tics, Kymera Ther­a­peu­tics and Cat­a­lyst Phar­ma­ceu­ti­cals: Boehringer In­gel­heim inks its third deal this week: